-

Simulations Plus to Participate in Upcoming Healthcare Conferences

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.

The Company will be presenting at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13-14, 2024. Shawn O’Connor, chief executive officer, will be presenting on Tuesday, February 13, 2024, at 11:20 a.m. Eastern Time, and he will be meeting with investors throughout both days. The live webcast of the Company’s presentation can be accessed via this link and also on the Investors page of the Simulations Plus website where it will be available for replay following the event. For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website.

The Company is also scheduled to host investor meetings at BTIG at Snowbird – BTIG’s 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place at the Cliff Lodge in Snowbird, Utah. CEO Shawn O’Connor will be meeting one-on-one with institutional investors on Tuesday and Wednesday, February 13-14, 2024. The Company’s slide presentation will be available on the Investors page of the Simulations Plus website. For more information about the BTIG conference, please visit the BTIG website.

About Simulations Plus, Inc.

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update.

Contacts

Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus will be participating in Oppenheimer's 34th Annual Healthcare Life Sciences Conference and BTIG at Snowbird on February 13-14, 2024.
Release Versions

Contacts

Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology...

Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit. The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-...

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simu...
Back to Newsroom